KRISTEN ROGERS: Open Payments
NPI 1407496268 · ROCKFORD, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,048 in 106 payments from 21 companies in 2025. Trend: 2023 $0 · 2024 $1,684 · 2025 $2,048
Food & beverage: $2,048
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $429 |
| AstraZeneca Pharmaceuticals LP | 8 | $239 |
| Novo Nordisk Inc | 10 | $197 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $164 |
| Lilly USA, LLC | 11 | $143 |
| GlaxoSmithKline, LLC. | 6 | $138 |
| Esperion Therapeutics, Inc. | 5 | $106 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $92 |
| Otsuka America Pharmaceutical, Inc. | 3 | $85 |
| Merck Sharp & Dohme LLC | 5 | $83 |
Products named: JARDIANCE, VRAYLAR, QULIPTA, FARXIGA, TRELEGY ELLIPTA, UBRELVY, NEXLETOL, REXULTI.
Industry payments across IL — which companies pay providers there.
